CoLucid Pharmaceuticals, inc. (NASDAQ: CLCD) was founded in 2005 in Cambridge, Massachusetts, USA, with 5 full-time employees. It is a biopharmaceutical company specializing in migraine research and treatment.
On March 1, 2017, Eli Lilly and Company completed the acquisition of CoLucid Pharmaceuticals for approximately US$960 million, and the latter’s stock was delisted.
CoLucid Pharmaceuticals (CLCD):
CoLucid was established in 2005 and is developing lasmiditan, an oral medicine for adult migraine, and lasmiditan, an emergency care for adults with unknown headache, intravenous injection. Lasmiditan is a new chemical vasoconstrictor drug designed to provide treatment for migraine that has not been cured for a long time. It is the so-called “ditans” (a new type of drugs penetrating the central nervous system)-selectively targeting the trigeminal nerve through the 5-HT1F receptor. It is currently in Phase III clinical trials (CoLucid has successfully completed 7 clinical studies of lasmiditan, including human trials on 391 migraine patients in Phase 2b).
CoLucid was founded by Pappas Ventures. Investors include Auriga Partners, Care Capital, Domain Associates, Novo Ventures, Pappas Ventures, Pearl Street Venture Funds, TVM Capital Life Science and Triathlon Medical Ventures (a group of venture capital companies, haha!).
CoLucid Pharmaceuticals (CLCD) investment:
CoLucid landed on Nasdaq on May 06, 2015. The planned issue price is US$13-15, and the actual issue price is US$10. The issue price fell below -20% on the first day of listing.